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Objectives. To evaluate blood monocyte subsets and functional monocyte properties in patients with rheumatoid arthritis (RA)
of short duration in the context of cardiovascular (CV) risk and disease activity. Methods. We studied conventional markers
of CV risk, intima media thickness (IMT), and blood monocyte subsets in 27 patients aged 41 ± 10 years with RA of short
duration (median 12 months) and 22 healthy controls. The RA subjects were divided into low (DAS28: 2.6–5.1) and high (DAS28
> 5.1) disease activity. Results. RA patients exhibited increased levels of intermediate (CD14++CD16+) monocytes with decreased
CD45RA expression compared to controls, increased counts of classical (CD14++CD16−) monocytes, and decreased percentages of
nonclassical (CD14+CD16++) monocytes. Patients with high disease activity had lower HLA DR expression on classical monocytes
compared to low disease activity patients.There were no differences in monocyte subsets between subjects with DAS > 5.1 and DAS
≤ 5.1.Therewere no significant intergroup differences in IMT and themajority of classical CV risk factors.Conclusions. Patients with
RA of short duration show alteration in peripheral blood monocyte subsets despite the fact that there is no evidence of subclinical
atherosclerosis. Disease activity assessed with DAS28 was associated with impaired functional properties but not with a shift in
monocyte subpopulations.
1. Introduction
Monocytes/macrophages play an important role in the patho-
genesis of rheumatoid arthritis (RA) [1], disease associated
with accelerated atherogenesis [2, 3]. They migrate into
joints and settle in the synovium and at the cartilage-pannus
junction, where they sustain inflammation and promote
proliferation of the synovium and joint destruction in both
the acute and the chronic phase of RA [1]. Activation of
monocytes is reflected by expression of major histocompat-
ibility complex (MHC) class II surface receptor—HLA-DR
[4] and by expression of antigen CD45RA [5]. Monocytes
produce proinflammatory cytokines such as interleukin-
(IL-) 1𝛽, IL-6, and tumor necrosis factor alpha (TNF-𝛼) [6].
These cytokines are released into the systemic circulation
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 736853, 10 pages
http://dx.doi.org/10.1155/2014/736853
2 BioMed Research International
resulting in endothelial activation/dysfunction [7] preced-
ing the formation of atherosclerotic lesion. 𝛽
2
-integrins
(CD11c/CD18, CD11b/CD18) are expressed onmonocytes and
their ligands (intercellular adhesion molecule-1 (ICAM-1),
vascular cell adhesion molecule-1 (VCAM-1))—on activated
endothelium [8, 9].
Due to increased integrin overexpression monocytes
adhere to activated endothelium and migrate into the arte-
rial wall, where foam cells arise from monocyte-derived
macrophages to form fatty streaks.
A key indicator of early vascular changes in the process of
atherosclerosis is an increased intima media thickness (IMT)
of the common carotid artery [10, 11]. It was shown previously
that RA patients have signs of subclinical atherosclerosis,
expressed by increased carotid IMT, even without traditional
CV risk factors [12] and an active disease was indepen-
dently associated with increased IMT [12, 13]. It has also
been established in other groups of patients without overt
cardiovascular disease that increased IMT heralds increased
risk for cardiac events and stroke [14].
Human monocytes consist of two major subpopulations,
classical (CD14++CD16−) monocytes constituting 80–90% of
blood monocytes and CD16+ monocytes, which are subdi-
vided into two subsets: intermediate (CD14++CD16+) and
nonclassical (CD14+CD16++) monocytes [15]. Furthermore,
there appears to be a developmental relationship between
monocyte subsets—from classical via intermediate to non-
classical [15]. Undeniably monocytes play important role in
the pathogenesis of both RA [1] and atherosclerosis [16].
However, it has not been established so far which subset of
monocytes is mainly involved in these processes. In the study
of Heine et al. [17], elevated level of intermediate monocytes
correlated with increased risk of ischemic cardiovascular
disease in end stage renal disease. Increased prevalence of
CD16+ monocytes has been reported by Kawanaka et al. in
the peripheral circulation of patients with active RA [18], but
without distinguishing between their subpopulations. Rossol
et al. pointed to a role and an expansion of the intermedi-
ate (CD14++CD16+) monocyte population in patients with
RA without growth within the population of nonclassical
(CD14+CD16+) monocytes [19]. Similar conclusions were
reached by Cooper et al. [20]. However, all the above studies
focused on patients with long-standing RA.
To the best of our knowledge, peripheral blood mono-
cytes heterogeneity has not been extensively studied in
patients with RA of short duration so far. Therefore, our goal
was to evaluate peripheral blood monocyte subpopulations
and their functional properties and to assess traditional CV
risk factors and signs of subclinical atherosclerosis in patients
with RA of short duration in relation to disease activity.
2. Methods
2.1. Study Population. We studied 27 adult patients, with
RA of short duration recruited from the group of patients
with arthritis referred to theOutpatient RheumatologyClinic
of the Department of Internal Diseases of the University
Hospital in Krakow as published previously [21], two patients
were excluded due to lack of flow cytometry results. The
diagnosis of RA was established according to the revised 1987
American College of Rheumatology (formerly, the American
RheumatismAssociation) criteria [22].The patients have had
disease duration of ≥6 weeks, have not been treated with any
biological or nonbiological disease-modifying antirheumatic
drugs (DMARDs), have been without any treatment (4
patients), or have been receiving stabile dose of nonsteroidal
anti-inflammatory drugs (NSAIDs) and/or steroids at least
4 weeks prior to enrollment in our study. Treatment with
DMARDs was given to all patients with diagnosis of RA
according to current guidelines directly after completion of
the study protocol. For all RA patients, DAS28 including
high-sensitivity C-reactive protein (hsCRP), the tender joint
count (28 joints), the swollen joint count (28 joints), and
the patient’s assessment of global well-being (100 mm visual
analogue scale, VAS) was calculated [23].We divided patients
with RA according to DAS28 into two groups: with high
(DAS28 > 5.1) and low (DAS28: 2.6–5.1) disease activity.
Three patients with DAS28 below 2.6 were excluded from
the subgroup analysis. Additionally, we studied 22 healthy
control subjects matched for sex and age.
Exclusion criteria, common for both groups, included
clinical evidence of atherosclerotic CV disease (coronary
artery disease, history of acute coronary syndrome, stroke/
transient ischemic attack, peripheral artery disease, and
symptomatic carotid artery stenosis), uncontrolled/
untreated hypertension, diabetes, renal failure, chronic
or acute infection, other autoimmune diseases, a history of
neoplastic disease within 5 years after treatment termination,
and current therapy with DMARDs.
2.2. Study Protocol. Patients were recruited from July 2009
to June 2011. The procedure was carried out in the morning
in the outpatient clinic. The subjects had been previously
asked to refrain from eating, smoking and alcohol, or caffeine
consumption for at least 12 h. All desired data, mainly on
smoking status, accompanying diseases and taking drugs
were collected according to prepared earlier questionnaire.
Blood pressure was measured 3 times on the left arm after 5
minutes of rest in a sitting position; values from2 last readings
were averaged. Mean arterial pressure (MAP) was calculated
using the following equation: [diastolic blood pressure +
1/3 (systolic blood pressure − diastolic blood pressure)].
Anthropometric measures including weight and height were
taken and body mass index (BMI) (body mass [kg]/height
[m]2) was calculated. Then all participants underwent blood
sampling for biochemical assays and flow cytometry. The
study protocol was approved by the Bioethical Committee
of Jagiellonian University and written informed consent was
obtained from all participants [21].
2.3. Biochemical Assays. Blood samples were taken from
the left antecubital vein. Serum lipids [total cholesterol
(TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-
C), triglycerides (TG)] and glucose levels were mea-
sured with a Hitachi 917 analyzer (Roche Diagnostics,
BioMed Research International 3
Hitachi Ltd., Japan) using standardized laboratory tech-
niques. High-sensitivity C-reactive protein (hsCRP) was
measured with immunonephelometry (Nephelometer BM II,
Siemens Health Care Diagnostics Inc., USA).
In RA patients, rheumatoid factor (RF) was determined
by immunoturbidimetric assay (APTEC Diagnostics nv.,
ALLmed Diagnostics) and anticyclic citrullinated peptide
antibodies (aCCP) with ELISA (QUANTA Lite CCP 3.1
IgG/IgA ELISA, INOVA Diagnostics, Inc., San Diego, USA).
2.4. Flow Cytometry. As described previously [24], periph-
eral blood mononuclear cells (PBMC) were isolated on
the day of collection from peripheral EDTA-anticoagulated
blood by density gradient centrifugation with LSM 1077
(Lymphocyte SeparationMedium, PAA Laboratories GmbH,
Austria). Cells (100.000) were stained for 20 minutes on ice
with fluorochrome-conjugated monoclonal antibodies (anti-
CD14-APC-H7, anti-CD16-PE, anti-HLA-DR-PE-Cy7, anti-
CD45RA-FITC, anti-CD11c-APC, and anti-CD11b-Pacific
Blue; Becton Dickinson (BD) Biosciences—Pharmingen, San
Diego, CA, USA) and then washed twice with phosphate
buffered saline (PBS) containing 1% heat inactivated fetal
bovine serum (FBS) (GIBCO). The cells were processed in
the FACSCanto II flow cytometer (BDBiosciences, CA, USA)
and then analyzed with FlowJo software (TreeStar Inc., Ash-
land, OR, USA). Cells were gated in a SSC (side scatter)/FSC
(forward scatter) plot with the scatter gate for monocytes
partially extending into lymphocytes [25]. The cells contain-
ing all monocytes and a part of the lymphocyte population
were then gated in an HLA-DR/CD14 plot to exclude HLA-
DR-negative natural killer cells (which would otherwise
contaminate the CD14+CD16++ subpopulation) and finally
were analyzed for CD14 and CD16 expression [25, 26].
Monocyte subsets were defined according to the expression
of CD16 (Fc𝛾 receptor type III) andCD14 (lipopolysaccharide
receptor) as classical monocytes (CD14++CD16−), intermedi-
ate monocytes (CD14++CD16+), and nonclassical monocytes
(CD14+CD16++) [15]. The expression of 𝛽
2
-integrins (CD11b
andCD11c), CD45RA, andHLA-DRon themonocyte subsets
was quantified.The results have been presented asMFI (mean
fluorescence intensity). Absolute numbers of monocytes per
𝜇L were calculated using peripheral white blood cell counts.
In separate experiments, BD Trucount beads were used,
confirming that bothmethods yielded similar absolute values
of cell counts.
2.5. Intima Media Thickness (IMT). Intima media thickness
of carotid arteries was measured in B-mode presentation
using GE Vivid 4 Ultrasound (GE Healthcare, Little, Chal-
font, UK) with 10MHz linear probe according to previously
published protocol [27]. IMT was measured bilaterally at
the proximal and distal walls 1 cm before bifurcation, at
the bifurcation of common carotid arteries, and 1 cm after
bifurcation in internal carotid arteries. Measurement was
gatedwith ECG.Analysis was performed off-line using Image
ProPlus software (Media Cybenetics Inc., Rockville, MD,
USA). The average value from 12 measurements was used in
analyses.
3. Statistics
Data are reported as mean (SD) or median (interquartile
range, IRQ) unless otherwise indicated. Proportions were
compared using Chi-square test or Fisher’s exact test in case
of small samples. Distribution of quantitative variables was
tested by Shapiro-Wilk and Kolmogorov-Smirnov tests. To
compare measures between the non-RA and RA patients,
Student’s 𝑡-test with independent estimation of variances or
Mann-Whitney test was used where appropriate.
Generalized Linear Models (GLM) were used to test dif-
ferences between the three groups: non-RA and RA subjects
with low andhighdisease activity—type III sumof squarewas
used. Homogeneity of variances was verified by Levene’s test.
The Bonferroni test was performed in post-hoc comparisons.
In case of lack of normal distribution Kruskal-Wallis test was
used.
Owing to multiple comparisons, two-tailed 𝑃 values
less than 0.01 were considered to be statistically significant.
Statistical analysis was performed by STATISTICA software
v.10 (StatSoft Inc.).
4. Results
Comparisons of monocyte subsets, CD45RA, HLA DR, and
𝛽
2
integrin expression and markers of cardiovascular risk
between RA patients and control subjects are presented in
Figure 1 and Tables 1 and 2.
Clinical and biochemical characteristics of RA patients
and control subjects in terms of traditional risk factors were
comparable. IMT was also comparable between the two
groups (Table 1). The mean values of traditional CV risk
factors in both groups were within normal range [14], except
for mean value of total cholesterol in control group, and LDL
cholesterol in both groups, that weremarginally elevated.The
percentage of patients with elevated levels of particular risk
factors was comparable in the study and control group (data
not shown). RA patients had increased hsCRP compared to
controls.
RA patients had an increased absolute number of mono-
cytes compared to controls. We observed increased num-
ber and percentage of intermediate (CD14++CD16+) mono-
cytes and an increased number of classical (CD14++CD16−)
monocytes and a decreased percentage of nonclassical
(CD14+CD16++) monocytes in RA patients in compari-
son with healthy subjects (Figure 1). RA patients exhib-
ited higher CD11c and HLA-DR expression on nonclassical
(CD14+CD16++) monocytes and lower CD45RA expression
on intermediate (CD14++CD16+) monocytes. There were no
differences in the monocyte CD11b expression in patients
when compared to the control group.
Comparisons of monocyte subsets, CD45RA, HLA DR,
𝛽
2
integrin expression, and conventional cardiovascular risk
factors in RA patients according to disease activity with the
reference to control subjects are presented in Figure 2 and
Tables 3 and 4.There were no significant differences between
patients with low and high disease activity in numbers and
percentages of monocyte subsets. However, in relation to
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Figure 1: Monocyte subsets in RA patients versus controls. Data are shown as means (SD) in % of monocytes (a) or per 𝜇L of blood (b). RA:
rheumatoid arthritis.
Table 1: Clinical characteristics and cardiovascular (CV) risk factors of RA patients and control subjects.
RA patients (𝑛 = 27) Control group (𝑛 = 22)
𝑃 value
Mean (SD) Mean (SD)
Clinical characteristics
Age, years 41.40 (9.65) 38.13 (10.84) 0.270
Female gender, 𝑛 (%) 21 (77.78%) 17 (77.27%) 1.000
Smoking habit, number (%) 12 (44.44%) 4 (18.18%) 0.069
RF positivity, 𝑛 (%) 25 (86%) — NA
aCCP positivity, 𝑛 (%) 24 (92.30%) — NA
Disease duration, months (median) 12 [4; 24] — NA
DAS28 4.42 (1.50) — NA
Steroids, number (%) 10 (37%) — NA
NSAIDs, number (%) 19 (70.37%) — NA
Without NSAIDs or steroids, number (%) 4 (14.8%) — NA
Antihypertensives, number (%) 2 (7.41%) 0 0.490
hsCRP, mg/L 15.92 (25.38) 1.03 (0.89) <0.001
Traditional CV risk factors
Systolic blood pressure, mmHg 121.77 (18.11) 113.86 (10.99) 0.066
Diastolic blood pressure, mmHg 80.03 (7.95) 75.27 (6.60) 0.041
Mean arterial pressure, mmHg 93.95 (10.50) 88.13 (7.18) 0.032
Body mass index, kg/m2 23.36 (4.09) 23.34 (2.72) 0.876
Glucose, mmol/L 4.64 (0.40) 5.02 (0.63) 0.015
TC, mmol/L 5.03 (1.24) 5.20 (0.70) 0.552
LDL-C, mmol/L 3.06 (0.96) 3.05 (0.74) 0.959
HDL-C, mmol/L 1.57 (0.41) 1.73 (0.45) 0.316
Triglycerides, mmol/L 0.94 (0.47) 0.93 (0.37) 0.795
IMT (mm) 0.43 (0.04) 0.48 (0.11) 0.114
Data are shown as means (SD) or medians [interquartile range, IRQ] or percentages (%). NA: not applicable; RA: rheumatoid arthritis; RF: rheumatoid factor;
aCCP: anticyclic citrullinated peptide antibodies; DAS28: disease activity score in 28 joints; NSAIDs: nonsteroidal anti-inflammatory drugs; hsCRP: high-
sensitivity C-reactive protein; TC: total cholesterol; LDL-C: low-density lipoproteins-cholesterol; HDL-C: high-density lipoproteins-cholesterol; IMT: intima
media thickness.
BioMed Research International 5
Table 2: Monocyte subpopulations and their characteristics (total count, expression of HLA-DR, CD45RA, and 𝛽
2
-integrins).
RA (𝑛 = 27) Control group (𝑛 = 22)
𝑃 value
Mean (SD) Mean (SD)
Monocytes total count (per 𝜇L of blood) 581.85 (220.24) 387.14 (110.15) <0.001
CD14++CD16− classical monocytes
CD45RA, MFI 646.92 (182.17) 780.31 (293.99) 0.028
CD11c, MFI 1574.44 (609.28) 1286.57 (1072.39) 0.018
CD11b, MFI 1468.07 (841.15) 1707.85 (1816.07) 0.581
HLA-DR, MFI 7781.88 (3777.45) 6116.86 (2040.72) 0.072
CD14++CD16+ intermediate monocytes
CD45RA, MFI 696.59 (199.02) 1079.45 (594.60) 0.001
CD11c, MFI 2809.56 (918.04) 2877.95 (2235.30) 0.289
CD11b, MFI 1647.30 (932.19) 1937.57 (2182.40) 0.546
HLA-DR, MFI 26656.89 (8883.37) 30188.32 (7584.79) 0.146
CD14+CD16++ nonclassical monocytes
CD45RA, MFI 1942.93 (589.65) 3512.00 (2599.85) 0.029
CD11c, MFI 5038.59 (1981.75) 3532.43 (2599.87) 0.002
CD11b, MFI 770.96 (365.94) 855.19 (738.51) 0.692
HLA-DR, MFI 32300.37 (11860.56) 21097.32 (8487.21) <0.001
Data are shown as means (SD). RA: rheumatoid arthritis; MFI: mean fluorescence intensity.
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Figure 2: Monocytes subpopulations according to DAS28. Data are shown as means (SD) in % of monocytes (a) or per 𝜇L of blood (b).
DAS28: disease activity score based on the assessment of 28 joints; low DAS28 = (2.6–5.1); high DAS28 = (>5.1). RA: rheumatoid arthritis; 𝑃
value in ANOVA (GLMmodels). ∗𝑃 < 0.01 versus control group in post-hoc analyses.
control group, RA patients with low disease activity exhib-
ited an increased number and percentage of intermediate
(CD14++CD16+) monocytes, whereas patients with high dis-
ease activity exhibited an increased absolute monocyte num-
ber and an increased number of classical (CD14++CD16−)
and intermediate (CD14++CD16+) monocytes. A number
of classical monocytes were slightly increased with higher
disease activity, but without statistical significance.
HLA-DR expression on classical (CD14++CD16−) mono-
cytes was higher in patients with lower disease activity than
in those with higher disease activity. A similar relationship
was observed for intermediate and nonclassical monocytes,
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Table 3: Traditional cardiovascular risk factors according to DAS28.
Control group
(𝑛 = 22)
RA patients with low DAS28∧
(𝑛 = 14)
RA patients with high DAS28∧
(𝑛 = 10) 𝑃 value
Mean (SD) Mean (SD) Mean (SD)
Age, years 38.13 (10.84) 39.92 (9.29) 43.60 (0.17) 0.385
Female gender, 𝑛 (%) 17 (77.27%) 11 (78.57%) 7 (70%) 0.878†
Smoking habit, number (%) 4 (18.18%) 5 (35.71%) 6 (60%) 0.024†
Steroids, number (%) — 3 (21.43%) 4 (40%) 0.616†
NSAIDs, number (%) — 8 (57.14%) 8 (80%) 0.490†
hsCRP, mg/L 1.03 (0.89) 5.43 (6.76)∗ 35.12 (33.74)∗ <0.001
Systolic blood pressure, mmHg 113.86 (10.99) 115.14 (16.87) 132.10 (16.65)∗ 0.004
Diastolic blood pressure, mmHg 75.27 (6.60) 78.35 (7.65) 82.90 (8.41)∗ 0.031
Mean arterial pressure, mmHg 88.13 (7.18) 90.61 (10.02) 99.30 (9.79)∗ 0.006
Body mass index, kg/m2 23.34 (2.72) 23.90 (3.68) 22.76 (4.73) 0.740
Glucose, mmol/L 5.02 (0.63) 4.58 (0.30) 4.80 (0.49) 0.063
TC, mmol/L 5.20 (0.70) 5.22 (1.33) 4.57 (1.16) 0.266
LDL-C, mmol/L 3.05 (0.74) 3.24 (0.99) 2.79 (0.97) 0.529
HDL-C, mmol/L 1.73 (0.45) 1.60 (0.45) 1.46 (0.38) 0.352
Triglycerides, mmol/L 0.93 (0.37) 0.85 (0.31) 0.82 (0.39) 0.726
IMT (mm) 0.48 (0.11) 0.43 (0.05) 0.42 (0.04) 0.208
Data are shown as means (SD). ∧Low DAS28 = (2.6–5.1); high DAS28 = (>5.1). RA: rheumatoid arthritis; DAS28: disease activity score in 28 joints; NSAIDs:
nonsteroidal anti-inflammatory drugs; hsCRP: high-sensitivity C-reactive protein; TC: total cholesterol; LDL-C: low-density lipoproteins-cholesterol; HDL-C:
high-density lipoproteins-cholesterol; IMT: intima media thickness.
𝑃value in ANOVA (GLMmodels). ∗𝑃 < 0.01 versus control group in post-hoc analyses †P: patients with low disease activity versus patients with high disease
activity.
Table 4: Monocyte subpopulations and their characteristics (total count, expression of HLA-DR, CD45RA, and 𝛽
2
-integrins) according to
DAS28.
Control group
(𝑛 = 22)
RA patients with low
DAS28∧
(𝑛 = 14)
RA patients with high
DAS28∧
(𝑛 = 10) 𝑃 value
Mean (SD) Mean (SD) Mean (SD)
Monocytes total count (per 𝜇L of blood) 387.14 (110.15) 508.57 (240.63) 661.00 (194.90)∗ 0.001
CD14++CD16− classical monocytes
CD45RA, MFI 780.30 (293.99) 621.00 (132.48) 696.70 (250.78) 0.174
CD11c, MFI 1286.57 (1072.39) 1448.64 (527.74) 1662.20 (722.06) 0.526
CD11b, MFI 1707.85 (1816.07) 1281.42 (684.76) 1644.80 (1087.00) 0.665
HLA-DR, MFI 6116.86 (2040.72) 9559.00 (4229.12)∗ 5628.70 (2141.07)# 0.001
CD14++CD16+ intermediate monocytes
CD45RA, MFI 1079.45 (594.60) 680.71 (161.28) 756.80 (253.02) 0.023
CD11c, MFI 2877.95 (2235.30) 2645.50 (874.77) 2886.20 (1051.87) 0.910
CD11b, MFI 1937.57 (2182.40) 1428.57 (786.51) 1798.60 (1134.00) 0.670
HLA-DR, MFI 30188.32 (7584.79) 31106.93 (8237.30) 21746.10 (8066.17) 0.011
CD14+CD16++ nonclassical monocytes
CD45RA, MFI 3512.00 (2599.85) 1764.64 (405.46) 2281.00 (713.70) 0.157
CD11c, MFI 3532.42 (2599.85) 4235.21 (1422.03) 5655.50 (2402.56) 0.060
CD11b, MFI 855.19 (738.51) 696.64 (368.87) 762.00 (317.71) 0.715
HLA-DR, MFI 21097.32 (8487.21) 35553.21 (11818.02)∗ 28167.20 (11481.66) <0.001
Data are shown as means (SD). ∧Low DAS28 = (2.6–5.1); high DAS28 = (>5.1). RA: rheumatoid arthritis; MFI: mean fluorescence intensity.
𝑃 value in ANOVA (GLMmodels). ∗𝑃 < 0.01 versus control group, #𝑃 < 0.01 versus RA patients with low disease activity in post-hoc analyses.
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however, without statistical significance. Additionally, com-
pared to control subjects, in patients with lower DAS28,
we observed higher HLA-DR expression on classical and
nonclassical monocytes.
With regard to traditional risk factors, patients with high
disease activity had increased systolic blood pressure and
MAP in relation to control subjects (Table 3).
5. Discussion
Patients with rheumatoid arthritis of short duration had
similar cardiovascular risk profile compared to controls.
Intima media thickness was also comparable between RA
patients and controls. Contrary to our results, IMT was
previously reported to be increased in RA patients with
recent disease onset [13], but those patients were older
(22–78 years old) and subjects with overt cardiovascular
disease were included in the study. In the recently published
meta-analysis of 22 studies related to carotid intima media
thickness in RA patients IMT was increased in 17 studies in
comparison to controls [28]. However, most of the studies
involved patients with long-standing disease and neither
disease duration nor disease activity but the presence of
cardiovascular risk factors had significant influence on IMT
differences observed between the groups. In the present
study, RA patients did not have subclinical atherosclerosis
which might be related to short duration of rheumatoid
arthritis and the lack of traditional CV risk factors in this
selected group of patients. Although increased incidence
of CV events in RA demonstrated in other studies is a
consequence of accelerated atherosclerosis [2], it cannot
be fully explained by traditional CV risk factors [29, 30].
Accelerated atherosclerosis accompanying RA is linked to
endothelial activation [21, 31] and dysfunction [32]. We have
previously shown [21] that patients with RA of short duration
exhibit endothelial activation (expressed by increased level
of soluble sVCAM-1, MCP-1, and von Willebrand factor and
pentraxin-3) that is an important factor in the development
of atherosclerosis.
We observed increased total monocytes number in
RA patients. Monocytosis has been described as an inde-
pendent marker of risk of stable coronary artery disease
and acute myocardial infarction [33]. Heine et al. revealed
that intermediate (CD14++CD16+) monocytes but not total
monocyte numbers predict cardiovascular events in dialysis
patients [17]. Moreover, Berg et al. showed that classical
(CD14++CD16−) monocytes can predict future CV risk inde-
pendently of other risk factors in a randomly selected popula-
tion [34]. Considering these findings, increased levels of both
intermediate and classical monocytes, which contributed to
elevated total monocytosis in our study, might precede the
subclinical changes in the arteries.
Assessing the distribution of monocyte subsets in
DMARDs-naı¨ve patients with RA of short duration, we
revealed higher percentage and number of intermedi-
ate (CD14++CD16+) monocytes and number of classical
(CD14++CD16−) peripheral blood monocytes and decreased
percentage of nonclassical (CD14+CD16++) monocytes in
comparison to the control group. Patients with high and
low disease activity had similar numbers and percentages of
monocyte subsets. Increased prevalence of CD16+ mono-
cytes in RA has previously been reported. Kawanaka et
al. reported higher frequency of CD16+ monocytes in the
peripheral blood of patients with RA [18], but without
distinguishing between subpopulations of CD16+monocytes.
Rossol et al. and Cooper et al., who analyzed three sub-
populations of monocytes, revealed in patients with RA an
expansion of the intermediate (CD14++CD16+) monocyte
population with no growth within the population of non-
classical (CD14+CD16+)monocytes [19, 20].However, studies
mentioned above considered mainly patients with long-
standing RA. Rossol et al. revealed no correlation between
expansion of intermediate (CD14++CD16+) monocytes and
the duration of RA, and intermediate monocytes remained
stable for up to 4 years in the longitudinal analysis [19].
Although patients with RA of short duration in our study
presented increased levels of intermediate monocytes, it did
not reflect their increased functional properties as HLA-
DR, CD45RA and CD11c expression in this subpopulation
of monocytes was not increased. The expression of CD45RA
on intermediate monocytes was significantly lower in RA
subjects than in healthy controls. CD45RA is considered a
marker of activation of peripheral blood monocytes [5]. It
was shown that activation of monocytes in vitro induces the
expression of CD45RA [35] and especially CD16 positive
monocytes exhibit high CD45RA expression [5, 36]. There-
fore, rather an increase in CD45RA expression onmonocytes
in RApatientsmight be expected. LowerCD45RA expression
may result from decreased number of activated cells in
peripheral blood due to theirmigration to inflammatory sites.
An interesting observation in our study is decreased
percentage of nonclassical monocytes in peripheral blood,
which may result from themigration of this monocyte subset
into the joints where they might contribute to synovial
inflammation. The previously published study revealed that
percentage of CD16+monocyteswas significantly increased in
synovial fluid, nearly four times higher compared to periph-
eral blood [18]. We found enhanced expression of CD11c
on nonclassical (CD14+CD16++) monocytes in RA patients
compared to healthy controls. Ancuta et al. demonstrated
that CD16+monocytes adhere to activated endothelium and
migrate into the jointmore efficiently than CD16−monocytes
due to increased adhesion molecule and chemokine receptor
expression [37, 38]. It has been shown lately that, in patients
with early RA [39] when compared to healthy controls, the
expression of CD11c was higher in both nonclassical and
classical monocyte subpopulations, and further nonclassical
monocytes displayed enhanced expression of CD11c com-
pared to classical and intermediate monocyte subpopula-
tions. Additionally, nonclassical (CD14+CD16++) monocytes
in our study, in spite of their lower percentage in RA
patients, are characterized by enhanced HLA-DR expression
compared to healthy controls, mainly in patients with low
disease activity.The upregulation of CD11c andHLA-DRmay
be related to the state of activation of nonclassical monocytes,
their higher antigen presentation capacity and enhanced
interaction with endothelial cells. Previously [21], in patients
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with RA of short duration we showed increased levels of
sVCAM-1 and MCP-1, endothelial activation markers asso-
ciated with monocyte adhesion. VCAM-1, upregulated in
endothelial cells in response to cytokines such as TNF-𝛼
and IL-1, is an endothelial ligand for CD11c/CD18, a 𝛽
2
-
integrin expressed on monocytes [9] and involved in mono-
cytes transendothelial migration [40]. Our results showing
increased expression of CD11c on nonclassical monocytes
may suggest enhanced interactions with endothelium and
their contribution to local inflammation.
We found in our study only increased number of classical
(CD14++CD16−) monocytes in patients with RA of short
duration in comparison to control subjects, with comparable
percentages of classical monocytes between RA patients and
controls. In the study of Cooper et al., in the group of early RA
patients, percentages of classical CD14++CD16+ monocytes
were not significantly different from healthy controls, but
long-standing RA patients had higher prevalence of classical
monocytes than patients with early disease [20]. Classical
monocytes are thought to correspond to murine peripheral
blood Ly-6Chigh monocytes, whose number increases in
conditions of inflammation and that are recruited into sites
of inflammation [41]. Moreover, elevated classical monocytes
were shown to predict CV events [34]. In our study, we
observed higher expression of HLA-DR on classical mono-
cytes in RA patients with lower disease activity than in
those with higher disease activity. It was observed also on
other monocyte subsets but without statistical significance.
Differential associations of inflammatory and endothelial
biomarkers with disease activity in RA of short duration
were discussed previously [21]. In the present study, higher
HLA-DR expression on classical monocytes, which indicates
their increased activation status, was shown despite lower
disease activity, which may suggest different mechanisms
involved in monocytes activation and in the level of systemic
inflammation assessed by disease activity score.
6. Study Limitations
There are some limitations to our study. First of all our
conclusions are constrained by low number of study par-
ticipants and a cross-sectional design of the study which
makes it impossible to follow changes in the relationship
between markers of inflammation, count and activity state
of monocytes in the course of disease. Second, we could not
eliminate influence of steroids on monocytes and endothelial
function in patients with rheumatoid arthritis. Third, the
results of the cells surface antigen expression may be affected
by the method used for leukocyte isolation.
7. Conclusions
Patients with rheumatoid arthritis of short duration show
increased total monocytosis and alteration in peripheral
blood monocyte subsets despite the fact that there is no evi-
dence of subclinical atherosclerosis. Disease activity assessed
with DAS28 was associated with impaired functional proper-
ties of monocytes but not with a shift in monocyte subpopu-
lations. Further studies are needed to establish whether these
alterations are relevant to the increased cardiovascular risk in
RA.
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